Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial

IMPORTANCE: There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. OBJECTIVES: To demonstrate manufacturing equivalence of a 3-antigen (3A) HBV vaccine, evaluate noninferiority of seroprotection rate (SPR) of 3A-HBV vs single-antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesikari, Timo, Finn, Adam, van Damme, Pierre, Leroux-Roels, Isabel, Leroux-Roels, Geert, Segall, Nathan, Toma, Azhar, Vallieres, Gerald, Aronson, Ronnie, Reich, Dennis, Arora, Samir, Ruane, Peter J., Cone, Clancy L., Manns, Michael, Cosgrove, Catherine, Faust, Saul N., Ramasamy, Maheshi N., Machluf, Nathalie, Spaans, Johanna N., Yassin-Rajkumar, Bebi, Anderson, David, Popovic, Vlad, Diaz-Mitoma, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511978/
https://www.ncbi.nlm.nih.gov/pubmed/34636914
http://dx.doi.org/10.1001/jamanetworkopen.2021.28652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511978/
https://www.ncbi.nlm.nih.gov/pubmed/34636914
http://dx.doi.org/10.1001/jamanetworkopen.2021.28652

Ejemplares similares